Finance

Beta
Lists
AVBP:NASDAQ
Arrivent Biopharma Inc
$32.70
+3.02%
(+0.96) 1D
$32.70
0.00% (0.00)
After hours
Closed: Jun 22, 4:00:01 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for AVBP...
Open
$32.18
High
$34.06
Low
$31.71
Mkt. cap
1.52B
Avg. vol.
517.16K
Volume
749.10K
52-wk high
$34.06
52-wk low
$16.10
EPS
-$3.52
Shares outstanding
46.58M
No. of employees
77
Open
$32.18
High
$34.06
Low
$31.71
Mkt. cap
1.52B
Avg. vol.
517.16K
Volume
749.10K
52-wk high
$34.06
52-wk low
$16.10
EPS
-$3.52
Shares outstanding
46.58M
No. of employees
77
News stories
From sources across the web
About Arrivent Biopharma Inc
CEO-
Employees77
Founded2021
HeadquartersNewtown Square, Pennsylvania, United States
SectorBiotechnology
Websitearrivent.com
Analyst Ratings
Based on 9 analysts giving stock ratings to AVBP in the past 3 months
Strong Buy
Buy
9
Hold
0
Sell
0
12 month forecast
Based on 9 Wall Street analysts offering 12 month price targets for AVBP in the last 3 months.
Highest
Current $32.70
$50.00 (+52.91%)
Average
$43.08 (+31.74%)
Lowest
$31.74 (-2.94%)
Analyst
Recommendation
Action
Price Target
Projected
Date
Supawat Thongthip
Truist Financial
Buy
Reiterated
$31.74
-2.9%
06/22/2026
Boris Peaker
JonesTrading
Buy
Maintained
$45.00
+37.6%
06/04/2026
Yigal Nochomovitz
Citi
Buy
Maintained
$43.00
+31.5%
06/03/2026
Michael Schmidt
Guggenheim
Buy
Maintained
$45.00
+37.6%
06/01/2026
Jeff Jones
Oppenheimer
Buy
Reiterated
$50.00
+52.9%
06/01/2026
Asthika Goonewardene
Truist Financial
Buy
Initiated
$45.00
+37.6%
05/29/2026
Jeet Mukherjee
BTIG
Buy
Maintained
$42.00
+28.4%
05/29/2026
Mayank Mamtani
B. Riley Securities
Buy
Maintained
$45.00
+37.6%
05/29/2026
Sam Slutsky
LifeSci Capital
Buy
Maintained
$42.00
+28.4%
05/16/2026
Robert Burns
H.C. Wainwright
Buy
Reiterated
$44.00
+34.6%
05/12/2026
Soumit Roy
JonesTrading
Buy
Maintained
$45.00
+37.6%
04/06/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
-
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
27.72M
32.17M
32.18M
37.62M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
5.90M
6.15M
6.65M
8.49M
Operating expense
33.62M
38.32M
38.82M
46.11M
Total operating expenses
33.62M
38.32M
38.82M
46.11M
Operating income
-33.62M
-38.32M
-38.82M
-46.11M
Other non operating income
-
-
-
-
EBT including unusual items
-31.40M
-34.75M
-35.96M
-43.32M
EBT excluding unusual items
-31.40M
-34.98M
-35.54M
-43.32M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-31.40M
-34.75M
-35.96M
-43.32M
Net profit margin
-
-
-
-
Earnings per share
-0.90
-0.83
-0.78
-0.96
Interest and investment income
2.22M
3.34M
3.28M
2.79M
Interest expense
-
-
-
-
Net interest expenses
2.22M
3.34M
3.28M
2.79M
Depreciation and amortization charges
-
-
-
-
EBITDA
-
-
-
-
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer